logo
Share SHARE
FONT-SIZE Plus   Neg

Chelsea To Discuss NORTHERA NDA For Treatment Of Symptomatic Neurogenic OH

Chelsea Therapeutics International, Ltd. (CHTP) said it will meet with the Food and Drug Administration's, or FDA's, Cardiovascular and Renal Drugs Advisory Committee on February 23, 2012 to review clinical data in support of the New Drug Application, or NDA, for NORTHERA (droxidopa).

Chelsea is seeking approval of NORTHERA for treating symptomatic neurogenic orthostatic hypotension, or Neurogenic OH, in patients with primary autonomic failure, dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy.

Dr. Simon Pedder, president and CEO of Chelsea, stated, "We have closely reviewed the materials prepared by the FDA, and look forward to presenting our clinical data to the Advisory Committee, which we believe will address the questions raised by the FDA. We believe that our clinical program has established robust safety and efficacy data for NORTHERA in this patient population."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Deutsche Bank AG declined around 4 percent in the morning trading after the German bank reported Wednesday sharply lower profit in its second quarter with significant one-time charges as well as weak revenues. John Cryan, CEO, said,".. if the current weak economic environment persists, we will need to be yet more ambitious in the timing and intensity of our restructuring." Shares of Airbus Group SE were gaining around 6 percent in the early morning trading in Paris after the aerospace and defense major reported Wednesday significantly higher profit in its second quarter, with positive one-offs items. Revenues, meanwhile, declined 1 percent with weakness in all segments. For fiscal 2016, the company continues to expect stable earnings per share. Shares of Apple Inc. (AAPL) gained 5 percent in extended trading session after the tech giant reported a third-quarter profit and revenues that trumped Wall Street expectations driven by higher-than-expected iPhone sales. Although, Apple reported its second year-over-year decline in iPhone sales,...
comments powered by Disqus
Follow RTT